Light-Activated drug tested to supercharge cancer treatment
NCT ID NCT04836429
Summary
This early safety study tested whether a special light-activated drug (photodynamic therapy) given during surgery could help the body's immune system fight advanced lung cancer more effectively when combined with immunotherapy. The trial enrolled 5 patients with non-small cell lung cancer that had spread to the lining of the lungs. Researchers primarily looked for serious side effects in the first month after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.